Molecular imaging of solid tumors: exploiting the potential

Area of Science:

• Oncology
• Molecular Imaging
• Pharmacodynamics

Background:

• Targeted cancer therapies often lead to disease stabilization, not shrinkage.
• Current assessment methods (e.g., tumor size) may not reflect the activity of novel agents.
• Long-term administration of targeted therapies necessitates new evaluation strategies.

Purpose of the Study:

• To highlight the need for noninvasive methods to assess molecular features of tumors during targeted therapy.
• To explore the potential of molecular imaging in predicting early treatment response and resistance.
• To determine if molecular imaging can inform therapy interruption decisions.

Main Methods:

• Review of current understanding of targeted therapy effects.
• Discussion of molecular imaging techniques, specifically Positron Emission Tomography (PET).
• Analysis of existing (small, retrospective) study data on molecular imaging in oncology.

Main Results:

• Changes in molecular features, not tumor size, may better indicate targeted therapy activity.
• Molecular imaging techniques like PET show potential for providing clinically relevant data.
• Current data is limited, primarily from small, observational studies.

Conclusions:

• Noninvasive molecular imaging is needed to evaluate early response and resistance to targeted cancer therapies.
• Further clinical trials are essential to validate molecular imaging's role in oncology practice.
• Molecular imaging could potentially guide treatment decisions and optimize therapy duration.